Kornimate/medical-research-clean huggingface dataset:
liquid biopsy system intracoronary blood sampling and analysis to characterise disease biomarkers in patients with coronary disease

Conditions: Coronary Artery Disease

Summary: the aim of this research, proposed and funded by plaquetec and co-ordinated by papworth trials unit collaboration, is to demonstrate the performance of the coronary artery blood sampling device (liquid biospy system, lbs) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest. using the data generated from extensive analysis of the blood samples, key biomarker data will be generated that will close a knowledge gap and facilitate the development of tailored treatments for coronary artery disease.


Eligibility criteria:
inclusion criteria: stage 1 screening inclusion: 1. ≥18 years of age, have capacity and be willing to provide informed consent to participate 2. clinical evidence of obstructive coronary artery disease and be scheduled for either: 1. elective coronary angiography +/- proceed for stable angina or 2. elective pci for stable angina with known bystander disease not for pci or 3. angiography +/- proceed for troponin negative unstable angina stage 2 screening inclusion: suitable lesion identified meeting angiographic criteria for lbs deployment and cardiologist comfortable to deploy oct and lbs on study lesion before carrying out pci on any other lesion exclusion criteria: stage 1 screening exclusion: 1. myocardial infarction within 30 days of procedure. 2. chronic renal failure (egfr\<30ml/min/1.73m2). 3. contrast allergy. 4. hypotension, shock or haemodynamic instability. 5. ventricular arrhythmia. 6. chronic heart failure (nyha ≥ 3) or lvef ≤ 30%. 7. immunocompromised or receiving immunosuppressant therapy. 8. any active disease that in the opinion of the investigator makes the subject unsuitable for the research procedure or subject life expectancy less than 1 year. 9. active infection or sepsis (significant crp elevation and/or requiring antibiotics). 10. active systemic inflammatory condition. 11. inability to receive anticoagulants or antiplatelets or uncorrected bleeding disorder or deranged platelet count. 12. is pregnant. 13. deemed high clinical risk or unsuitable for the procedure for any reason by the treating clinician. stage 2 screening exclusion: 1. target lesion is in the left main coronary artery. 2. target lesion requires pci 3. in same vessel as lesion requiring pci 4. unsuitable coronary anatomy (vessel tortuosity \[\>45 degree bend\], moderate/ severe calcification angiographically, ostial disease). 5. presence of thrombus in the target vessel. 6. prior pci or stent in vessel identified for lbs sampling

Keywords: liquid biopsy system intracoronary biomarkers plaquetec biopattern
the effect of task-oriented emg-triggered es on upper limb motor function in hemiplegic cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: the purpose of our study; to investigate the effects of emg-induced es treatment on hand functions, muscle strength, and quality of life in patients with hemiplegic cp.

upper limb spasticity greatly affects the hand functions of patients with cerebral palsy (cp) and impairs quality of life. the most important goal in rehabilitation; despite the existing deficiencies, the highest level of functional independence of the patient is to increase the quality of life. emg-triggered biofeedback electrical stimulation (emg-triggered-bf-es) increases the patient's active participation and motivation in rehabilitation, creates visual or auditory bf, provides muscle reeducation, decreases spasticity, prevents atrophies and increases joint mobility and increases muscle functionality by increasing the patient's functionality. there are areas of use the emg-triggered-bf-es such as cerebrovascular disease (cvo), spinal cord injury, and cp. when the literature is examined; studies were found to be few, and no study evaluating the upper extremity was found in children with cp. the purpose of our study is the investigation of the effects of emg-triggered-bf-es treatment applied on hand functions, muscle strength, and quality of life in patients with cp.

Eligibility criteria:
inclusion criteria: * having a diagnosis of cp * age between 4 and 18 year * at least 10° of the active wrist and finger extension in the affected limb but less than normal * upper limb spasticity (shoulder, elbow, wrist, and fingers) less than or equal to grade 2 according to the modified ashworth scale (mas) * should be able to receive command exclusion criteria: * mental retardation * passive range of motion (rom) limitation in the upper extremity * sensory impairment in the upper extremity * the visual and auditory deficit in the upper extremity * mas is more than 3. * botulinum toxin application to the upper limb in the last 6 months * any surgical application to the upper limb in the last 6 months

Keywords: cerebral palsy task-oriented training
mp diagnostics htlv blot 2.4 post-market clinical study

Conditions: HTLV-I Infections; HTLV-II Infections; Human T-lymphotropic Virus 1; Human T-lymphotropic Virus 2; HTLV I Associated T Cell Leukemia Lymphoma; HTLV I Associated Myelopathies

Summary: this post-market study is intended to assess the performance of the htlv blot 2.4 in repository serum/plasma specimens with neurological disorders (n=100) or an htlv known positive infection (n=50).

the htlv blot 2.4 post-market clinical study is an open-label, multi-center, single-blind clinical study of neurological disorders (n=100) and htlv known-positive (kp) specimens (n=50). this study is being conducted to support additional labeling claims and to further assess the sensitivity and specificity of the htlv blot 2.4 in specimens with neurological disorders and htlv known positive specimens.

Eligibility criteria:
inclusion criteria: all specimens: * male or female * biorepository specimen de-identified of phi * specimen meets htlv blot 2.4 labeling collection/handling criteria htlv positive specimens: specimens with a known positive infection of htlv i, htlv ii or htlv i/ii neurological disorders: specimens with a diagnosis or symptoms consistent with any of the following neurological disorders: * acute disseminated encephalitis * amyotrophic lateral sclerosis (als) * autonomic dysfunction * conus medularis syndrome * chronic inflammatory demyelinating polyneuropathy * dermatomyositis * htlv associated myelopathy-tropical spastic paraparesis (ham-tsp) * meningitis * mild cognitive impairment * multiple sclerosis (ms) * polymyositis * spastic paraparesis * sciatica exclusion criteria: htlv infected: * specimens with a known infection or history of hiv, hcv or hbv * specimens not meeting specimen labeling collection / handling criteria neurological disorders * specimens not meeting specimen labeling collection / handling criteria

Keywords: htlv confirmatory supplemental blot htlv-i htlv-ii
the canadian hiv quit smoking trial: tackling the co-morbidities of depression and cardiovascular disease in hiv+ smokers

Conditions: HIV; Smoking Cessation

Summary: the objectives of this trial are: primary objectives: 1. to determine among hiv+ individuals whether varenicline or nrt is more effective at helping individuals remain abstinent from smoking tobacco. 2. to determine among hiv+ individuals whether varenicline or nrt has the lowest side-effect profile. 3. to determine if the hiv tailored quit smoking counselling intervention, plus smoking cessation drug therapy, improves smoking cessation rates compared to smoking cessation drug therapy alone with usual care. secondary objective: 1. to determine whether the use of varenicline/nrt is safe in hiv+ patients who exhibit depressive symptoms. hypothesis: that varenicline will result in higher quit smoking rates and that nrt will result in a lower side effect profile. further, the hiv tailored quit smoking intervention will result in higher rates of smoking cessation over and above the pharmacological treatment alone. and finally, varenicline will be safe to use for hiv + individuals who exhibit depressive symptoms.


Eligibility criteria:
inclusion criteria: 1. hiv positive 2. adult (aged 18 or older) 3. current smoker (more than 5 cigarettes per day) 4. willing to set a date to quit smoking within the next 2-4 weeks 5. currently on art with an undetectable hiv viral load 6. able to read/speak english or french 7. able to provide written, informed consent as approved by the ottawa health science network research ethics board and rebs at participating hiv clinic sites exclusion criteria: 1. contraindications to nicotine replacement therapy such as allergy to adhesive, serious cardiac arrhythmias (e.g., tachycardia), or vasospastic disease (e.g., buerger's disease, prinzmetal's variant angina) 2. contraindications to varenicline such as hypersensitivity to varenicline or to any ingredient in the formulation or component of the container. 3. reported previous severe intolerances to nausea or gastrointestinal symptoms. 4. pregnant, lactating or planning to become pregnant during the study period or refuses a serum beta-hcg test. 5. current severe renal impairment or currently taking cimetidine 6. previous or current seizure disorder and/or is taking anti-epileptic drugs 7. psychosis and/or is taking anti-psychotic drugs 8. diagnosed with severe major depressive episode requiring hospitalization within the past 12 months, previous psychiatric inpatient admission for any cause within the past 12 months, suicide attempt within the past 12 months active or current suicidal ideations as assessed by the bdi-ii. 9. current use of bupropion, varenicline or any nicotine replacement therapy. 10. use of substances (e.g., crack cocaine) that would interfere with a participant's ability to adhere to the study schedule; determined by site coordinator's discretion.
novara registry of platinum-chromium platform stents

Conditions: Fracture of Stent of Coronary Artery; External Causes of Morbidity and Mortality; Myocardial Infarction; Coronary Vessel Disorders

Summary: recent reports have described cases of novel thin-strut coronary stent longitudinal deformation during or after deployment and a biomechanical analysis have suggested increased susceptibility for such a complication for the platinum chromium (ptcr) coronary stent platforms . this analysis aims to assess the incidence of longitudinal stent deformation for ptcr stents in a large single centre all-comers population using quantitative angiographic analysis (qca).

aims: recent reports have described cases of novel thin-strut coronary stent longitudinal deformation during or after deployment and a biomechanical analysis have suggested increased susceptibility for such a complication for the platinum chromium (ptcr) coronary stent platforms . the aim of this analysis is to assess the incidence of longitudinal stent deformation for ptcr stents in a large single centre all-comers population . methods: quantitative angiographic analysis (qca) of ptcr stents deployed in consecutive all-comers patients treated in our laboratory from january 2011 to august 2012 will be performed by an independent core laboratory. in particular qca : nominal stent lenght ratio will be calculated for every ptcr stent. clinical follow up with data about overall and cardiac mortality, myocardial infarction and target vessel revascularization will also be performed.

Eligibility criteria:
inclusion criteria: * pci with at least 1 platinum-chromium platform-based stent * presence of at least 2 ortogonal angiographic projections of the deployed stent to allow proper quantitative coronary angiography exclusion criteria: * age \ 90

Keywords: platinum-chromium stents concertina effect stent deformation everolimus eluting stents stent lenght
musculoskeletal effects of isotretinoin during acne treatment in pediatric population

Conditions: Acne

Summary: this is a prospective study, that will follow participants over their course of treatment on isotretinoin. all patients who are prescribed isotretinoin for their acne treatment are registered in ipledge. the ipledge program involves a set of steps that the patient, physician and pharmacist must follow for the patient to take isotretinoin. patients will be asked if they are willing to participate in this research study to determine musculoskeletal changes in adolescents and young adults on systemic therapy using the highly sensitive magnetic resonance (mr) imaging modality. in addition to the mri, participants will be asked if they are willing to give an extra sample of blood when their routine blood work is being done for ipledge. this blood sample will be used to determine if there are any effects of isotretinoin on bone turnover markers.


Eligibility criteria:
inclusion criteria: 1. registered in i-pledge and has not started the isotretinoin medication 2. females and males ages 12-21 years old 3. able to undergo 3 mri scan exclusion criteria: 1. participants taking additional vitamin a, d or calcium supplements 2. previous musculoskeletal injuries (from incidental trauma, sports related injury or motorvehicle accidents, etc) 3. clinical diagnosis of psoriasis, rheumatoid arthritis and/or reiter's disease 4. relocation within the next 6 months 5. participation on a research study involving drug medication within the past 30 days
body mass index and post-dural puncture headache

Conditions: This Study Investigated the Influence of Body Mass Index (BMI) on PDPH in Elective Caesarean Section Patients in Whom 27G Spinal Needles Were Used

Summary: post-dural puncture headache (pdph) is seen more frequently in pregnant women due to stress, dehydration, intra-abdominal pressure, and insufficient fluid replacement after delivery. obesity protects against pdph in pregnant women; increased intra-abdominal fat tissue reduced cerebrospinal fluid leakage by increasing the pressure in the epidural space. therefore, this study investigated the influence of body mass index (bmi) on pdph in elective caesarean section patients in whom 27g spinal needles were used.

the study included 420 women with american society of anesthesiology physical status i-ii who underwent elective caesarean section under spinal anesthesia. the patients with a bmi less than 30 were accepted as normal weight (group i) and those with a bmi above 30 were accepted as obese (group ii). dural puncture performed with a 27g quincke spinal needle at the l3-4 or l4-5 intervertebral space and given 12.5 mg hyperbaric bupivacaine intrathecally. the patients were questioned regarding headache and low back pain 6, 12, 24, and 48 hours after the procedure, and by phone calls on days 3 and 7.

Eligibility criteria:
inclusion criteria: (asa) physical status i-ii who underwent elective caesarean section under sa. women age 18-40 years. exclusion criteria: * who had undergone lumbar disc or vertebra surgery, had chronic low back pain or headache, had contraindications for neuro-axial block, and emergency patients.
zoledronic acid in the prevention of skeletal-related events in hormone refractory and hormone-sensitive prostate cancer patients with bone metastases

Conditions: Prostate Cancer

Summary: the present study will give information about the course over time in skeletal-related events (sre) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg administered as a 15-minute infusion every 4 weeks for a maximum of 15 infusions. the protocol will enroll patients with recent diagnosis of bone metastases from prostate cancer who are hormone-refractory, hormone-naïve or still hormone-sensitive, that represent the entire population of prostate cancer patients


Eligibility criteria:
inclusion criteria * patients aged ≥18 years * written informed consent * histologically-proven prostate carcinoma * ecog performance status ≤ 2 * life expectancy \> 6 months * newly diagnosed (≤ 6 months prior to visit 1) bone metastases evidenced by bone scan or radiograph. * patients on androgen deprivation therapy (medical therapy with lhrh analogues + antiandrogens or surgical castration) or going to start it * patients with partners of childbearing potential should use a barrier method of contraception throughout the study exclusion criteria * patients without a history of metastatic disease to the bone * prior treatment with bisphosphonates * sres prior to visit 2 * prior treatment with calcitonin, mithramycin, or gallium nitrate within 2 weeks prior to baseline * corrected (adjusted for serum albumin - see appendix 5 for the calculation) serum calcium concentration \< 8.0 mg/dl (2.00 mmol/l) * serum creatinine concentration \> 265 micromol/l (3.0 mg/dl) or a calculated creatinine clearance \< 30 ml/minute or serious underlying renal disease or prior renal transplantation * history of other malignant neoplasm within previous five years with exception of non-melanomatous skin cancer which has been satisfactorily treated * other known concurrent, severe medical disorder jeopardizing the life of the patient in the immediate future * patients treated with systemic investigational drug(s) and/or device(s) within the past 30 days or topical investigational drugs within the past 7 days * known hypersensitivity to zoledronic acid or other bisphosphonates * history of noncompliance to medical regimens and patients who are considered potentially unreliable (for example drug or alchohol abusers) or incapable of giving informed consent as judged by the investigator

Keywords: zoledronic acid prostate cancer sre
the effect of music listening in rehabilitation of subacute stroke

Conditions: Ischemic Stroke; Intracerebral Hemorrhage

Summary: music listening has many positive effects on the brain. this study aims to find out if people with stroke get better results with their rehabilitation if they listen to music during their passive hours. the study is a randomized controlled trial with people who are at a rehabilitation center care after stroke at tampere university hospital. the control group gets standard rehabilitation. music group gets standard rehabilitation and in addition they listen to music one hour a day during four weeks. physiotherapists, occupational therapists and speech therapists test how well the participant's walking, use of hand and speech improve. the main goal is to find out if the improvement is better with music listening. the study also monitors effects of music listening on mood in rehabilitation.


Eligibility criteria:
inclusion criteria: * hemispheric stroke (ischemic or intracerebral hemorrhage) during last 4 weeks or spinal cord injury in last 6 months, causing a need of intensive rehabilitation exclusion criteria: * severe hearing loss preventing music listening * previous condition of neurological disease of dementia that significantly affects daily functions * active drug use or acute psychiatric condition * unable to understand given information and give consent to participate * for spinal cord injury patients: acute traumatic brain injury or stroke
intraarticular analgesia after total hip arthroplasty, a randomised study

Conditions: Arthroplasty, Replacement, Hip

Summary: the purpose of this study is to determine whether wound infiltration with following single-shot bolus injection with local anesthetic and nasids are effective in the treatment of postoperative pain after total hip replacement compared to continuous epidural infusion.

sufficient postoperative pain relief after total hip replacement is necessary to achieve normal mobilisation and a reduction of the surgical stress response. after total hip replacement epidural treatment has proven superior, with regards to pain relief, than treatment with parenteral infusions and periphery nerve blocks. even though epidural treatment gives excellent pain relief adverse effect as motor block, urine retention, hypotension and itching occurs regularly which delays rehabilitation. treatment with the administration of local anesthetic in the operating field has shown its efficiency in reducing postoperative pain with a low incidence of adverse effects after various surgical procedures. this study compares continuous epidural infusion of ropivacaine added morphine to a new technique, where ropivacaine, ketorolac and adrenaline is used to infiltrate the tissue around the hip joint during surgery, and is injected by an intraarticular catheter 8 hours postoperative. data of pain scores, analgesia consumption, adverse effects and mobilisation is collected for the first 4 postoperative days.

Eligibility criteria:
inclusion criteria: * patients admitted consecutively to primary total hip arthroplasty due to arthrosis exclusion criteria: * patients unable to provide informed consent * patients with contraindications for spinal anesthesia * patients with known hypersensitivity towards the used drugs * patients with severe chronic neurogenic pain * patients with rheumatoid arthritis * patients with a daily opioid consumption

Keywords: arthroplasty, replacement, hip anesthetics, local pain, postoperative
gender related differences in the acute effects of delta-9-tetrahydrocannabinol in healthy humans

Conditions: Cannabis

Summary: the purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.


Eligibility criteria:
inclusion criteria: * at least one lifetime exposure to cannabis * good physical and mental health exclusion criteria: * cannabis naive individuals * major current or recent stressors * taking estrogen supplements or oral contraceptive pills (for women)
efficacy, and safety study of optimized background antiretroviral regimen (ob) in combination with enfuvirtide in the treatment-experienced participants with human immunodeficiency virus-1 (hiv-1) infection

Conditions: HIV Infections

Summary: this is an open-label, randomized and multi-center study to compare the efficacy and safety of continued enfuvirtide (fuzeon) plus (+) ob therapy versus ob alone in participants with hiv-1 infection. participants will receive an initial 28 week induction treatment with enfuvirtide + ob. after 28 weeks participants with a plasma viral load less than or equal to (\</=) 400 copies/milliliter (ml) at week 16 and less than (\<) 50 copies/ml at week 24 will be randomized in the ratio 1:1 to receive either enfuvirtide + ob or ob alone for another 24 weeks (up to week 52).


Eligibility criteria:
inclusion criteria: * participants with hiv-1 infection * female participants without any risk of pregnancy * participants previously treated with drugs of 2 or 3 different antiretroviral classes * participants currently on highly active antiretroviral treatment (haart) for more than 4 weeks and with a plasma viral load between 1,000 and 300,000 copies of hiv-1 ribonucleic acid per milliliter (rna/ml) * participants with the possibility of potentially effective ob without enfuvirtide, consisting to 2 to 5 drugs, at least two of which are active from at least two different antiretroviral classes * cluster of differentiation 4 (cd4) cell count greater than (\>) 50 cells/cubic millimeter (mm\^3) at screening * participants in whom resistance mutations have been detected in reverse transcriptase and/or protease genes * enfuvirtide-naive participants exclusion criteria: * women of childbearing age not using effective mechanical contraception * pregnant or breastfeeding women * presence of hiv-2 coinfection * participants participating or having participated to another clinical trial during the 30 days prior to selection for this trial * participants having previously been treated with enfuvirtide * presence active opportunistic infection within 1 month of study entry * existence of grade 4 clinical or laboratory abnormalities * cirrhosis or severe hepatic failure * uncontrolled diabetes or requiring insulin * consumption of alcohol and/or narcotics and/or other substances